Go Deep
X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 21,870 | 130.0 | 1.66 | 0.50 | 247.61 |
| Oct 2026 | 22,081 | 122.5 | 1.56 | 0.50 | 232.62 |
| Oct 2026 | 21,814 | 132.0 | 1.68 | 0.50 | 250.70 |
| Oct 2026 | 21,884 | 129.5 | 1.65 | 0.50 | 245.31 |
| Oct 2026 | 21,660 | 137.5 | 1.75 | 0.50 | 260.75 |
| Oct 2026 | 21,280 | 151.0 | 1.93 | 0.50 | 286.35 |
| Oct 2026 | 21,295 | 150.5 | 1.92 | 0.50 | 284.69 |
| Oct 2026 | 21,028 | 160.0 | 2.04 | 0.50 | 302.05 |
X4 Pharmaceuticals, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 8,806,000.0 | 2,708,000.0 | 2,568,000.0 | 1,765,000.0 |
| Net Profit | -16,157,000.0 | -20,241,000.0 | -23,925,000.0 | -29,815,000.0 |
| EPS | -0.1 | -0.2 | — | -0.7 |
X4 Pharmaceuticals, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 35,113,000.0 | 2,557,000.0 | 0.0 | 0.0 | — |
| Net Profit | -79,199,000.0 | -37,450,000.0 | -101,167,000.0 | -93,867,000.0 | — |
| EPS | -1.9 | -5.7 | -17.1 | -45.6 | — |
X4 Pharmaceuticals, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 290,461,000.0 | 146,447,000.0 | 147,258,000.0 | 155,586,000.0 | — |
| Total Liabilities | 104,171,000.0 | 124,298,000.0 | 96,159,000.0 | 81,535,000.0 | — |
| Total Equity | 186,290,000.0 | 22,149,000.0 | 51,099,000.0 | 74,051,000.0 | — |
Owes vs Owns
X4 Pharmaceuticals, Inc. owed $0.39 for every $1 it owned in Jun 2026, down from $0.52 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.39× | 0.36× | 0.85× | 0.65× | 0.52× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
X4 Pharmaceuticals, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 87.1%Inventory 1.5%Fixed assets (tangible) 0.5%Intangible assets 9.2%Other assets 1.5%
How it's funded — Dec 2025
Long-term debt 26.3%Payables 2.0%Other liabilities 7.3%Shareholders' equity 64.1%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 253.0 | 102.1 | 114.2 | 121.7 |
| Receivables | 0.6 | 1.7 | 0.6 | 1.2 |
| Inventory | 4.5 | 2.8 | 0.0 | 0.0 |
| Fixed assets (tangible) | 1.6 | 4.8 | 6.4 | 8.3 |
| Intangible assets | 26.6 | 27.4 | 17.4 | 17.4 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 4.2 | 7.7 | 8.7 | 7.0 |
| Liabilities & equity | ||||
| Short-term debt | 1.0 | 1.3 | 1.1 | 1.3 |
| Long-term debt | 76.3 | 75.4 | 54.6 | 32.3 |
| Payables | 5.7 | 8.6 | 8.9 | 7.8 |
| Other liabilities | 21.2 | 39.0 | 31.5 | 40.1 |
| Shareholders' equity | 186.3 | 22.1 | 51.1 | 74.1 |
| Net tangible assets | 159.7 | -5.2 | 33.7 | 56.7 |
X4 Pharmaceuticals, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -85,618,000.0 | -130,901,000.0 | -96,512,000.0 | -77,102,000.0 | — |
| Investing Activities | 8,154,000.0 | 66,990,000.0 | -14,883,000.0 | -103,000.0 | — |
| Financing Activities | 238,628,000.0 | 20,294,000.0 | 88,516,000.0 | 117,230,000.0 | — |